Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years
Survival has improved in bladder cancer but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed survival in urothelial cancer (UC, of which vast majority are bladder cancers) in Finland and Sweden over a 50-year period...
Gespeichert in:
Veröffentlicht in: | PloS one 2022-01, Vol.17 (1), p.e0261124-e0261124 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | e0261124 |
---|---|
container_issue | 1 |
container_start_page | e0261124 |
container_title | PloS one |
container_volume | 17 |
creator | Hemminki, Kari Försti, Asta Hemminki, Akseli Ljungberg, Börje Hemminki, Otto |
description | Survival has improved in bladder cancer but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed survival in urothelial cancer (UC, of which vast majority are bladder cancers) in Finland and Sweden over a 50-year period (1967-2016) using data from the NORDCAN database. Finland and Sweden are neighboring countries with largely similar health care systems but higher economic resources and health care expenditure in Sweden. We present results on 1- and 5-year relative survival rates, and additionally provide a novel measure, the difference between 1- and 5-year relative survival, indicating how well survival was maintained between these two periods. Over the 50-year period the median diagnostic age has increased by several years and the incidence in the very old patients has increased vastly. Relative 1- year survival rates increased until early 1990s in both countries, and with minor gains later reaching about 90% in men and 85% in women. Although 5-year survival also developed favorably until early 1990s, subsequent gains were small. Over time, age specific differences in male 1-year survival narrowed but remained wide in 5-year survival. For women, age differences were larger than for men. The limitations of the study were lack of information on treatment and stage. In conclusion, challenges are to improve 5-year survival, to reduce the gender gap and to target specific care to the most common patient group, those of 70 years at diagnosis. The most effective methods to achieve survival gains are to target control of tobacco use, emphasis on early diagnosis with prompt action at hematuria, upfront curative treatment and awareness of high relapse requiring regular cystoscopy follow up. |
doi_str_mv | 10.1371/journal.pone.0261124 |
format | Article |
fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2616581567</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A688645163</galeid><doaj_id>oai_doaj_org_article_5358b441b23c439aa74dbcde17920db7</doaj_id><sourcerecordid>A688645163</sourcerecordid><originalsourceid>FETCH-LOGICAL-c730t-f8302e2636ccdb3432277c1141067af9cc13ead33721ee46bd36024680b3e4223</originalsourceid><addsrcrecordid>eNqNk11v0zAYhSMEYmPwDxBEQkJw0eKv2MkNUjUYVJo0icIuuLEc22ldpXZmxx379zhtNzVoF8iKbNnPOcp77DfLXkMwhZjBT2sXvRXttHNWTwGiECLyJDuFFUYTigB-erQ-yV6EsAagwCWlz7MTTKoSsQqfZr8X0W_NVrS5sXndCqW0z4VVeey6tIreWOHv8t4L2edSWKl9GNALY9sBG77FrVba5v3Ku7hc5QXI77Tw4WX2rBFt0K8O81n26-Lrz_Pvk8urb_Pz2eVEMgz6SVNigDSimEqpakwwQoxJCAkElImmkhJiLRTGDEGtCa0VpgARWoIaa4IQPsve7n271gV-iCXwlAgtSlhQloj5nlBOrHnnzSbVxJ0wfLfh_JIL3xvZal7goqwJgTXCkuBKCEZULZWGrEJA1YPXZO8VbnUX65HbF3M927nFTeSwgojRxH8-_F2sN1pJbVOW7Ug2PrFmxZduy0uGKGFlMvhwMPDuJurQ840JUrcpfu3ivs6qKPAOffcP-ngaB2opUsHGNm643cGUz2hZUlJAihM1fYRKQ-mNkenNNSbtjwQfR4LE9PpPvxQxBD5f_Ph_9up6zL4_YldatP0quDb2xtkwBskelN6F4HXzEDIEfGiZ-zT40DL80DJJ9ub4gh5E9z2C_wK2GA9u</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2616581567</pqid></control><display><type>article</type><title>Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>SWEPUB Freely available online</source><source>Public Library of Science (PLoS)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Hemminki, Kari ; Försti, Asta ; Hemminki, Akseli ; Ljungberg, Börje ; Hemminki, Otto</creator><contributor>Roemer, Klaus</contributor><creatorcontrib>Hemminki, Kari ; Försti, Asta ; Hemminki, Akseli ; Ljungberg, Börje ; Hemminki, Otto ; Roemer, Klaus</creatorcontrib><description>Survival has improved in bladder cancer but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed survival in urothelial cancer (UC, of which vast majority are bladder cancers) in Finland and Sweden over a 50-year period (1967-2016) using data from the NORDCAN database. Finland and Sweden are neighboring countries with largely similar health care systems but higher economic resources and health care expenditure in Sweden. We present results on 1- and 5-year relative survival rates, and additionally provide a novel measure, the difference between 1- and 5-year relative survival, indicating how well survival was maintained between these two periods. Over the 50-year period the median diagnostic age has increased by several years and the incidence in the very old patients has increased vastly. Relative 1- year survival rates increased until early 1990s in both countries, and with minor gains later reaching about 90% in men and 85% in women. Although 5-year survival also developed favorably until early 1990s, subsequent gains were small. Over time, age specific differences in male 1-year survival narrowed but remained wide in 5-year survival. For women, age differences were larger than for men. The limitations of the study were lack of information on treatment and stage. In conclusion, challenges are to improve 5-year survival, to reduce the gender gap and to target specific care to the most common patient group, those of 70 years at diagnosis. The most effective methods to achieve survival gains are to target control of tobacco use, emphasis on early diagnosis with prompt action at hematuria, upfront curative treatment and awareness of high relapse requiring regular cystoscopy follow up.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0261124</identifier><identifier>PMID: 34982793</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Age ; Age differences ; Age groups ; Aged ; Aged, 80 and over ; Bladder ; Bladder cancer ; Cancer ; Cancer survivors ; Cancer therapies ; Chemotherapy ; Databases, Factual ; Demographic aspects ; Diagnosis ; Epidemiology ; Female ; Finland - epidemiology ; Follow-Up Studies ; Gender aspects ; Gene therapy ; Health care ; Health services ; Hematuria ; Humans ; Immunology ; Incidence ; Male ; Medical diagnosis ; Medical prognosis ; Medical research ; Medicine and Health Sciences ; Men ; Middle Aged ; Patient outcomes ; Patients ; People and places ; Skin cancer ; Statistics ; Survival ; Survival Rate - trends ; Sweden - epidemiology ; Tobacco ; Tobacco Use ; Trends ; Tumors ; Urinary Bladder Neoplasms - diagnosis ; Urinary Bladder Neoplasms - epidemiology ; Urinary Bladder Neoplasms - mortality ; Urinary tract ; Urogenital system ; Urologic Neoplasms - diagnosis ; Urologic Neoplasms - epidemiology ; Urologic Neoplasms - mortality ; Urology ; Urothelial cancer ; Women</subject><ispartof>PloS one, 2022-01, Vol.17 (1), p.e0261124-e0261124</ispartof><rights>COPYRIGHT 2022 Public Library of Science</rights><rights>2022 Hemminki et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 Hemminki et al 2022 Hemminki et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c730t-f8302e2636ccdb3432277c1141067af9cc13ead33721ee46bd36024680b3e4223</citedby><cites>FETCH-LOGICAL-c730t-f8302e2636ccdb3432277c1141067af9cc13ead33721ee46bd36024680b3e4223</cites><orcidid>0000-0002-2769-3316</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8726478/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8726478/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,552,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793,79600,79601</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34982793$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-191276$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><contributor>Roemer, Klaus</contributor><creatorcontrib>Hemminki, Kari</creatorcontrib><creatorcontrib>Försti, Asta</creatorcontrib><creatorcontrib>Hemminki, Akseli</creatorcontrib><creatorcontrib>Ljungberg, Börje</creatorcontrib><creatorcontrib>Hemminki, Otto</creatorcontrib><title>Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Survival has improved in bladder cancer but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed survival in urothelial cancer (UC, of which vast majority are bladder cancers) in Finland and Sweden over a 50-year period (1967-2016) using data from the NORDCAN database. Finland and Sweden are neighboring countries with largely similar health care systems but higher economic resources and health care expenditure in Sweden. We present results on 1- and 5-year relative survival rates, and additionally provide a novel measure, the difference between 1- and 5-year relative survival, indicating how well survival was maintained between these two periods. Over the 50-year period the median diagnostic age has increased by several years and the incidence in the very old patients has increased vastly. Relative 1- year survival rates increased until early 1990s in both countries, and with minor gains later reaching about 90% in men and 85% in women. Although 5-year survival also developed favorably until early 1990s, subsequent gains were small. Over time, age specific differences in male 1-year survival narrowed but remained wide in 5-year survival. For women, age differences were larger than for men. The limitations of the study were lack of information on treatment and stage. In conclusion, challenges are to improve 5-year survival, to reduce the gender gap and to target specific care to the most common patient group, those of 70 years at diagnosis. The most effective methods to achieve survival gains are to target control of tobacco use, emphasis on early diagnosis with prompt action at hematuria, upfront curative treatment and awareness of high relapse requiring regular cystoscopy follow up.</description><subject>Age</subject><subject>Age differences</subject><subject>Age groups</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Bladder</subject><subject>Bladder cancer</subject><subject>Cancer</subject><subject>Cancer survivors</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Databases, Factual</subject><subject>Demographic aspects</subject><subject>Diagnosis</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Finland - epidemiology</subject><subject>Follow-Up Studies</subject><subject>Gender aspects</subject><subject>Gene therapy</subject><subject>Health care</subject><subject>Health services</subject><subject>Hematuria</subject><subject>Humans</subject><subject>Immunology</subject><subject>Incidence</subject><subject>Male</subject><subject>Medical diagnosis</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine and Health Sciences</subject><subject>Men</subject><subject>Middle Aged</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>People and places</subject><subject>Skin cancer</subject><subject>Statistics</subject><subject>Survival</subject><subject>Survival Rate - trends</subject><subject>Sweden - epidemiology</subject><subject>Tobacco</subject><subject>Tobacco Use</subject><subject>Trends</subject><subject>Tumors</subject><subject>Urinary Bladder Neoplasms - diagnosis</subject><subject>Urinary Bladder Neoplasms - epidemiology</subject><subject>Urinary Bladder Neoplasms - mortality</subject><subject>Urinary tract</subject><subject>Urogenital system</subject><subject>Urologic Neoplasms - diagnosis</subject><subject>Urologic Neoplasms - epidemiology</subject><subject>Urologic Neoplasms - mortality</subject><subject>Urology</subject><subject>Urothelial cancer</subject><subject>Women</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>D8T</sourceid><sourceid>DOA</sourceid><recordid>eNqNk11v0zAYhSMEYmPwDxBEQkJw0eKv2MkNUjUYVJo0icIuuLEc22ldpXZmxx379zhtNzVoF8iKbNnPOcp77DfLXkMwhZjBT2sXvRXttHNWTwGiECLyJDuFFUYTigB-erQ-yV6EsAagwCWlz7MTTKoSsQqfZr8X0W_NVrS5sXndCqW0z4VVeey6tIreWOHv8t4L2edSWKl9GNALY9sBG77FrVba5v3Ku7hc5QXI77Tw4WX2rBFt0K8O81n26-Lrz_Pvk8urb_Pz2eVEMgz6SVNigDSimEqpakwwQoxJCAkElImmkhJiLRTGDEGtCa0VpgARWoIaa4IQPsve7n271gV-iCXwlAgtSlhQloj5nlBOrHnnzSbVxJ0wfLfh_JIL3xvZal7goqwJgTXCkuBKCEZULZWGrEJA1YPXZO8VbnUX65HbF3M927nFTeSwgojRxH8-_F2sN1pJbVOW7Ug2PrFmxZduy0uGKGFlMvhwMPDuJurQ840JUrcpfu3ivs6qKPAOffcP-ngaB2opUsHGNm643cGUz2hZUlJAihM1fYRKQ-mNkenNNSbtjwQfR4LE9PpPvxQxBD5f_Ph_9up6zL4_YldatP0quDb2xtkwBskelN6F4HXzEDIEfGiZ-zT40DL80DJJ9ub4gh5E9z2C_wK2GA9u</recordid><startdate>20220104</startdate><enddate>20220104</enddate><creator>Hemminki, Kari</creator><creator>Försti, Asta</creator><creator>Hemminki, Akseli</creator><creator>Ljungberg, Börje</creator><creator>Hemminki, Otto</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>ADHXS</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>D93</scope><scope>ZZAVC</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-2769-3316</orcidid></search><sort><creationdate>20220104</creationdate><title>Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years</title><author>Hemminki, Kari ; Försti, Asta ; Hemminki, Akseli ; Ljungberg, Börje ; Hemminki, Otto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c730t-f8302e2636ccdb3432277c1141067af9cc13ead33721ee46bd36024680b3e4223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Age</topic><topic>Age differences</topic><topic>Age groups</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Bladder</topic><topic>Bladder cancer</topic><topic>Cancer</topic><topic>Cancer survivors</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Databases, Factual</topic><topic>Demographic aspects</topic><topic>Diagnosis</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Finland - epidemiology</topic><topic>Follow-Up Studies</topic><topic>Gender aspects</topic><topic>Gene therapy</topic><topic>Health care</topic><topic>Health services</topic><topic>Hematuria</topic><topic>Humans</topic><topic>Immunology</topic><topic>Incidence</topic><topic>Male</topic><topic>Medical diagnosis</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine and Health Sciences</topic><topic>Men</topic><topic>Middle Aged</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>People and places</topic><topic>Skin cancer</topic><topic>Statistics</topic><topic>Survival</topic><topic>Survival Rate - trends</topic><topic>Sweden - epidemiology</topic><topic>Tobacco</topic><topic>Tobacco Use</topic><topic>Trends</topic><topic>Tumors</topic><topic>Urinary Bladder Neoplasms - diagnosis</topic><topic>Urinary Bladder Neoplasms - epidemiology</topic><topic>Urinary Bladder Neoplasms - mortality</topic><topic>Urinary tract</topic><topic>Urogenital system</topic><topic>Urologic Neoplasms - diagnosis</topic><topic>Urologic Neoplasms - epidemiology</topic><topic>Urologic Neoplasms - mortality</topic><topic>Urology</topic><topic>Urothelial cancer</topic><topic>Women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hemminki, Kari</creatorcontrib><creatorcontrib>Försti, Asta</creatorcontrib><creatorcontrib>Hemminki, Akseli</creatorcontrib><creatorcontrib>Ljungberg, Börje</creatorcontrib><creatorcontrib>Hemminki, Otto</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SWEPUB Umeå universitet full text</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SWEPUB Umeå universitet</collection><collection>SwePub Articles full text</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hemminki, Kari</au><au>Försti, Asta</au><au>Hemminki, Akseli</au><au>Ljungberg, Börje</au><au>Hemminki, Otto</au><au>Roemer, Klaus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2022-01-04</date><risdate>2022</risdate><volume>17</volume><issue>1</issue><spage>e0261124</spage><epage>e0261124</epage><pages>e0261124-e0261124</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Survival has improved in bladder cancer but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed survival in urothelial cancer (UC, of which vast majority are bladder cancers) in Finland and Sweden over a 50-year period (1967-2016) using data from the NORDCAN database. Finland and Sweden are neighboring countries with largely similar health care systems but higher economic resources and health care expenditure in Sweden. We present results on 1- and 5-year relative survival rates, and additionally provide a novel measure, the difference between 1- and 5-year relative survival, indicating how well survival was maintained between these two periods. Over the 50-year period the median diagnostic age has increased by several years and the incidence in the very old patients has increased vastly. Relative 1- year survival rates increased until early 1990s in both countries, and with minor gains later reaching about 90% in men and 85% in women. Although 5-year survival also developed favorably until early 1990s, subsequent gains were small. Over time, age specific differences in male 1-year survival narrowed but remained wide in 5-year survival. For women, age differences were larger than for men. The limitations of the study were lack of information on treatment and stage. In conclusion, challenges are to improve 5-year survival, to reduce the gender gap and to target specific care to the most common patient group, those of 70 years at diagnosis. The most effective methods to achieve survival gains are to target control of tobacco use, emphasis on early diagnosis with prompt action at hematuria, upfront curative treatment and awareness of high relapse requiring regular cystoscopy follow up.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>34982793</pmid><doi>10.1371/journal.pone.0261124</doi><tpages>e0261124</tpages><orcidid>https://orcid.org/0000-0002-2769-3316</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1932-6203 |
ispartof | PloS one, 2022-01, Vol.17 (1), p.e0261124-e0261124 |
issn | 1932-6203 1932-6203 |
language | eng |
recordid | cdi_plos_journals_2616581567 |
source | MEDLINE; DOAJ Directory of Open Access Journals; SWEPUB Freely available online; Public Library of Science (PLoS); EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
subjects | Age Age differences Age groups Aged Aged, 80 and over Bladder Bladder cancer Cancer Cancer survivors Cancer therapies Chemotherapy Databases, Factual Demographic aspects Diagnosis Epidemiology Female Finland - epidemiology Follow-Up Studies Gender aspects Gene therapy Health care Health services Hematuria Humans Immunology Incidence Male Medical diagnosis Medical prognosis Medical research Medicine and Health Sciences Men Middle Aged Patient outcomes Patients People and places Skin cancer Statistics Survival Survival Rate - trends Sweden - epidemiology Tobacco Tobacco Use Trends Tumors Urinary Bladder Neoplasms - diagnosis Urinary Bladder Neoplasms - epidemiology Urinary Bladder Neoplasms - mortality Urinary tract Urogenital system Urologic Neoplasms - diagnosis Urologic Neoplasms - epidemiology Urologic Neoplasms - mortality Urology Urothelial cancer Women |
title | Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T23%3A53%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20in%20bladder%20and%20upper%20urinary%20tract%20cancers%20in%20Finland%20and%20Sweden%20through%2050%20years&rft.jtitle=PloS%20one&rft.au=Hemminki,%20Kari&rft.date=2022-01-04&rft.volume=17&rft.issue=1&rft.spage=e0261124&rft.epage=e0261124&rft.pages=e0261124-e0261124&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0261124&rft_dat=%3Cgale_plos_%3EA688645163%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2616581567&rft_id=info:pmid/34982793&rft_galeid=A688645163&rft_doaj_id=oai_doaj_org_article_5358b441b23c439aa74dbcde17920db7&rfr_iscdi=true |